2[1]Slerdal L,Spigset O.Heart failure induced by non-cardiac drugs[J].Drug Safety,2006,29(7):567-586.
3[2]Minotti G,Menna P,Salvatorelli E,et al.Anthracyclines:molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity[J].Pharmacol Rev,2004,56(2):185-229.
4[3]Jensen BV,Skovsgaard T,Nielsen SL.Functional monitoring of anthracycline cardiotoxicity:a prospective,blinded,longterm observational study of outcome in 120 patients[J].Ann Oncol,2002,13 (5):699-709.
5[5]Pai VB,Nahata MC.Cardiotoxicity of chemotherapeutic agents:incidence,treatment,and prevention[J].Drug Saf,2000,22(4):263-302.
6[6]Yeh ET,Tong AT,Lenihan DJ,et al.Cardiovascular complications of cancer therapy:diagnosis,Pathogenesis,and management[J].Circulation,2004,109(25):3122-3131.
7[7]Yeh ET.Cardiotoxicity induced by chemotherapy and antibody therapy[J].Annu Rev Med,2006,57:485-498.
8[8]Seidman A,Hudis C,Pierri MK,et al.Cardiac dysfunction in the trastuzumab clinical trials experience[J].J Clin Oncol,2002,20(5):1215-1221.
9[9]Feenstra J,Heerdink ER,Grobbe DE,et al.Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure:the Rotterdam Study[J].Arch Intern Med,2002,162(3):265-270.
10[10]Mamdani M,Juurlind DN,Lee DS,et al.Cyclo-oxygenase2inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients:a population-based cohort study[J].Lancet,2004,363:175-176.
